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Abstract
Many patients with Alzheimer's dementia (AD) also exhibit noncognitive symptoms
such as sensorimotor deficits, which can precede the hallmark cognitive deficits and
significantly impact daily activities and an individual's ability to live independently.
However, the mechanisms underlying sensorimotor dysfunction in AD and their rela-
tionship with cognitive decline remains poorly understood, due in part to a lack of
translationally relevant animal models. To address this, we recently developed a novel
model of genetic diversity in Alzheimer's disease, the AD-BXD genetic reference
panel. In this study, we investigated sensorimotor deficits in the AD-BXDs and the
relationship to cognitive decline in these mice. We found that age- and AD-related
declines in coordination, balance and vestibular function vary significantly across the
panel, indicating genetic background strongly influences the expressivity of the famil-
ial AD mutations used in the AD-BXD panel and their impact on motor function.
Although young males and females perform comparably regardless of genotype on
narrow beam and inclined screen tasks, there were significant sex differences in
aging- and AD-related decline, with females exhibiting worse decline than males of
the same age and transgene status. Finally, we found that AD motor decline is not
correlated with cognitive decline, suggesting that sensorimotor deficits in AD may
occur through distinct mechanisms. Overall, our results suggest that AD-related sen-
sorimotor decline is strongly dependent on background genetics and is independent
of dementia and cognitive deficits, suggesting that effective therapeutics for the
entire spectrum of AD symptoms will likely require interventions targeting each dis-
tinct domain involved in the disease.
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1 | INTRODUCTION
Alzheimer's dementia (AD) is defined by the slow progression of cog-
nitive deficits, including memory loss and dementia, accompanied by
the accumulation of β-amyloid (Aβ) plaques and hyperphosphorylated
tau tangles.1 However, patients with AD often experience additional
noncognitive symptoms that significantly impact daily life for both
patients and caregivers and lead to an inability to live independently,
requiring long-term care.2-6 Among these noncognitive symptoms are
deficits in sensorimotor function such as gait slowing, loss of balance
and coordination, sarcopenia and muscle weakness and increased
frailty. Furthermore, the emergence of these symptoms during the
preclinical stage of AD is associated with worse AD-related cognitive
decline than in individuals who do not exhibit motor-related
symptoms.4
Development of motor deficits prior to the hallmark memory loss
associated with AD2,3 suggests that they may represent some of the
very earliest events in the pathogenesis of AD. Unfortunately, motor
dysfunction and other noncognitive symptoms in AD are poorly
understood compared with the cognitive deficits and memory loss so
closely associated with the disease. It therefore remains unknown
whether motor impairment represents an early biomarker of disease,
or if it is part of a chain of causal events leading to dementia. It is
essential to determine whether AD-related decline in cognitive and
motor function share a common mechanism. If shared pathogenesis
exists Understanding the causal factors underlying motor symptoms
may enhance our ability to identify new pathways for therapeutics
that address both domains. Alternatively, if they have distinct causal
mechanisms, then therapies targeting cognitive symptoms may be
ineffective in treating motor dysfunction and thus, fail to prevent or
delay the loss or independence or the need for long-term
institutional care.
Significant progress in understanding the pathophysiology of AD
has been made using mouse models incorporating familial mutations
in amyloid precursor protein (APP) and/or presenilin-1 (PSEN1), origi-
nally designed to recapitulate the cognitive symptoms of AD. Notably,
several of these models have been reported to also exhibit sensorimo-
tor deficits, suggesting that motor impairments are an inherent part of
the disease process.7-13 However, infrequent assessment of motor
phenotypes in AD animal models, variability in the tests used to assess
motor function, and use of a single sex has led to conflicting reports
on the impact of AD transgenes on motor function.7,10,11,14,15
The etiology of AD in humans is complex and although age is the
greatest risk factor for developing AD, it is increasingly clear that
genetics and family history play a significant role.16,17 Most animal
models are developed on single or a few inbred backgrounds,18 with
little or no genetic variation, presenting a challenge for identifying and
investigating AD symptoms such as motor dysfunction, which can
vary considerably in its presentation in human populations. As such, a
major barrier to understanding the overlap (or lack thereof) of mecha-
nisms underlying motor dysfunction and cognitive symptoms in AD is
a paucity of translationally relevant animal models that recapitulate
individual differences in symptom onset and progression in the human
population.
To address this, we recently developed the AD-BXD panel,19
which combines the well-characterized 5XFAD model of AD20 with
the BXD genetic reference panel21,22 to create a novel AD model that
incorporates both causal AD mutations and naturally-occurring
genetic diversity to better model the human disease. In the present
study, we assess the impact of AD, normal aging and naturally occur-
ring genetic variation on sensorimotor-related phenotypes and their
relationship to cognitive outcomes using the AD-BXD panel. Because
the panel also includes the nontransgenic controls, we can distinguish
the influence of familial AD mutations from the normal decline in
motor skills commonly observed in aging. We hypothesized that the
AD-BXD panel would exhibit age-related decline in sensorimotor
function that is exacerbated by the presence of the AD transgene and
that diverse genetic backgrounds would influence the expressivity of
the 5XFAD transgene to modify the onset and severity of motor-
related phenotypes.
2 | METHODS
2.1 | Mice
Generation of the AD-BXD panel was described in detail in Refer-
ences.19 Briefly, female congenic C57Bl/6J mice hemizygous for the
5XFAD transgene20 (MMRRC Stock No: 34848-JAX) were crossed to
male mice from strains selected from the BXD genetic reference
panel.21 The resulting F1 offspring are isogenic recombinant inbred
mice carrying one maternally derived B allele and one paternally
derived B or D allele at each genomic locus. Furthermore, ~50% of F1
mice carry the 5XFAD transgene (termed AD-BXD), while the other
~50% are nontransgenic littermate controls (termed Ntg-BXDs). Mice
from a total of 27 Ntg- and AD-BXD (27 female, 18 male) strains were
used in this study; mice were genotyped for the 5XFAD transgene by
either the Transgenic Genotyping Service at The Jackson Laboratory
or Transnetyx, Inc. All mice were fed a standard laboratory mouse
chow (Teklad 8604) and both food and water were available ad
libitum. All mice were kept on a 12:12 light cycle and were phe-
notyped as previously described.19
All experiments involving mice were performed at the University
of Tennessee Health Science Center and were approved by the Insti-
tutional Care and Use Committee at that institution and carried out in
accordance with the standards of the Association for the Assessment
and Accreditation of Laboratory Animal Care (AAALAC) and the NIH
Guide for the Care and Use of Laboratory Animals.
2.2 | Sensorimotor phenotyping
Sensorimotor function was assessed at 6 and 14 months of age in the
Ntg-BXD and AD-BXD panels. A total of 894 mice (575 female,
319 male) across a total of 27 AD- and Ntg-BXD strains were included
in this study. The sensorimotor tasks used were narrow beam, negative
geotaxis (incline screen) and grip strength.19 Narrow beam: Briefly, the
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narrow beam task was used to assess motor and balance coordination
by placing each mouse in the center of a 1 m long beam 12 mm wide
that was elevated 50 cm above a table surface (Maze Engineers, Bos-
ton, Massachusetts). The time taken in seconds for each mouse to cross
the beam to a safe platform on either side was recorded. A maximum
time limit of 180 seconds was imposed; if a mouse fell from the beam,
the maximum time of 180 seconds was given. The average of three tri-
als for the task was used to assess the performance for each mouse and
the average used for statistical analysis.
Incline screen: The incline screen task was used to assess vestibular
and/or proprioceptive function. Each mouse was placed nose-down in
the center of a wire mesh grid (1 × 1 cm) positioned at a 45 angle
(Harvard Apparatus). The time taken for a mouse to reorient itself with
its nose facing upwards (negative geotaxis) was recorded; the average
of three trials for each mouse was used for analysis. As with narrow
beam, a 180 seconds maximum time limit for righting was used.
Grip strength: Muscle strength was measured using a standard
grip strength meter. Each mouse was placed horizontally on the wire
grid of the apparatus (Columbus Instruments) with all four paws
grasping the grid and then gently pulled away from the grid by the
base of its tail until its grip released to measure the force exerted.
The average of three trials for each mouse was recorded and used
for analysis.
2.3 | Data analysis and availability
All data and statistical analysis were performed using R (version 3.5.3).
A univariate ANOVA was used for each sensorimotor task using geno-
type, age, sex and strain as fixed factors. Data are reported as mean
± SE of the mean in both the main text and figure legends. A two-
sided Pearson's correlation test was used to assess the relationship of
decline between the Ntg-BXD and AD-BXD on these tasks. CFA and
CFM measures used for correlations in Figures 3 and 5 are from.19 All
raw data used in this study are available through the Synapse AMP-
AD Knowledge Portal (https://www.synapse.org/#!Synapse:
syn17016211). Strain averaged behavioral data has also been depos-
ited at GeneNetwork.org. Heritability estimates for the sensorimotor
phenotypic traits in the AD- and Ntg-BXDs were determined by cal-
culating the ratio of between-strain variance to total sample variance
(variance due to both genetic and technical/environmental factors)
according to.23
3 | RESULTS
3.1 | Balance and motor coordination are impaired in
AD-BXD mice in a genetic-background dependent
manner
Since balance and coordination skills are often impaired in human AD
patients,3 we assessed these sensorimotor domains in the AD-BXD
panel using the narrow beam task, which is a well-characterized and val-
idated assay for balance and coordination in mice.24,25 To determine
the impact of genetic background on AD- and age-related impairments
in these domains, we measured performance on the narrow beam appa-
ratus in 27 strains of AD-BXD mice (27 strains female, 18 strains male)
at 6 and 14 months (m) of age. We also tested age-matched Ntg-BXD
strains to assess the impact of normal aging on this task.
As shown in Figure 1A, as a population, AD-BXD mice took signifi-
cantly longer to cross the beam compared with the non-carrier con-
trols (Genotype: F1,886 = 24.5, P < .0001). There was a main effect of
age on narrow beam performance (6 m v 14 m: F1, 886 = 3.9, P < .05)
and presence of the AD transgene significantly exacerbated age-
related decline (Age*Genotype: F1,886 = 7.6, P < .005) (Figure 1B).
Post hoc comparisons using the Tukey HSD test indicated that this
effect was primarily driven by the presence of the AD transgene and
was not due to decline due to normal aging, as there was no
F IGURE 1 Presence of the high-risk AD transgene impairs motor coordination and balance in an age- and sex-dependent manner. (A) Mice
carrying the 5XFAD transgene take significantly longer to cross the narrow beam apparatus, indicating impaired balance and coordination.
(B) Stratification of narrow beam performance by age and (C) by age and sex. Each point represents a strain average and statistical outliers are
indicated by a + sign. *** = adj. P < .0001 following post hoc testing using Tukey's HSD
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significant effect of age in the Ntg-BXD (6 m-14 m, adj. P > .1). Fur-
thermore, although there was a trend for 6 m AD-BXD mice to per-
form worse on this task than their age-matched Ntg-BXD controls,
this difference was not significant (adj. P > .1). Lastly, although there
was no significant main effect of sex on narrow beam performance
across the panel (Sex: F(1, 886) < 1, n.s.), there were significant interac-
tions between both age and sex (Age*Sex: F(1, 886) = 9.16, P < .005)
and sex and genotype (Sex*Genotype: F(1, 886) = 7.9, P < .005), with
post hoc comparisons suggesting that impairment due to age and AD
status was greater in females than males (Figure 1C).
To assess the influence of genetic background on balance and
coordination, we compared narrow beam performance across the
Ntg- and AD-BXD strains phenotyped in this study. As shown in
Figure 2, genetic background plays a significant role in narrow beam
performance as evidenced by a significant main effect of background
strain in both the Ntg- (black bars) and AD-BXD strains (red bars)
(StrainNtg: F(26, 363) = 3.35, P < .0001; StrainAD: F27,474) = 2.7,
P < .0001) and a high degree of heritability for this task (Table 1). As
expected from our population-level analyses, although there is a sig-
nificant main effect of strain at both 6 and 14 m in the Ntg-BXDs
(Figure 2A,B, left panels), there is no effect of age, with most Ntg-BXD
strains performing as well or better at 14 m compared with 6 m
(Figure 2C). On the other hand, both age and background strain were
significant in the AD-BXD population (Figure 2, right panels),
suggesting that age related decline is exacerbated in most (but not all)
AD-BXD strains. Notably, although there are significant main effects
of both strain and genotype as described above, there is no significant
correlation between the Ntg- and AD-BXD strains on narrow beam
performance in either males (r = .24, P > .1, df = 15) or females
(r = .27, P > .1, df = 21) (Figure 3A), suggesting that genotype*strain
interactions have a greater impact on narrow beam performance than
strain alone. Consistent with the pronounced influence of background
strain, heritability (h2RIx) estimates comparing the between-strain vari-
ance (an estimate of variation due to genetic factors) to total sample
variance (an estimate of variation due to environmental, technical and
genetic factors) indicate that genetic factors significantly influence
phenotypic variation (Table 1).
The AD-BXD panel exhibits significant strain-dependent cognitive
decline,19 so to determine whether cognitive performance in this panel
correlates with sensorimotor ability, we assessed the relationship
between narrow beam performance and memory as measured using
the contextual fear memory task.19 We found no significant correlation
between motor performance and either short-term memory (CFA, con-
textual fear acquisition) or long-term memory (contextual fear memory,
CFM; from Reference19) in either Ntg- or AD-BXD mice of either sex
(Figure 3B,C), suggesting that the mechanism(s) underliying deficits in
balance and coordination are, in part, unrelated to aging or AD-related
cognitive impairment in this panel of mice.
3.2 | AD-related impairments in motor coordination
and vestibular function
Human AD patients often exhibit impairments in balance and orienta-
tion suggestive of deficits in vestibular function and proprioception,
domains that are assessed in mice using the inclined screen test. In
this test, mice are placed head down on a wire mesh screen fixed at a
45 angle and their natural reflex to reposition themselves head up
measured, with longer righting times suggestive of impairments in
proprioceptive and vestibular systems.26 There was a significant effect
of AD genotype on this task (Figure 4A), with AD-BXD mice requiring
significantly longer time to reorient themselves than Ntg-BXD mice
F IGURE 2 Genetic background
influences motor coordination and
balance on the narrow beam task in
both normal aging and AD. (A) Mean
time to cross the narrow beam
averaged by strain in 6 m old Ntg-
BXD (left) and AD-BXD (right)
strains. (B) Mean time to cross the
narrow beam averaged by strain in
14 m old Ntg-BXD (left) and AD-
BXD (right) strains. (C) Average age-
related decline by strain in the Ntg-
BXD (left) and AD-BXD (right)
panels. Decline was calculated by
subtracting performance at 6 m of
age from that measured at 14 m of
age. Data are presented as mean
± SEM. In all panels, number on the
x-axis indicates the BXD strain used
to generate each line.
*** = P < .0001
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(Genotype: F[1886] = 55.21, P < .0001). There was also a significant
effect of age on inclined screen performance (Figure 4B), with 14 m
old mice taking significantly longer than 6 m old mice (Age:
F(1,886) = 59.8, P < .0001). For this task, there was a significant interac-
tion between age and genotype (Age*Genotype: F(1,886) = 20.33,
P < .0001). As with the narrow beam task, post hoc multiple compari-
sons indicated that Ntg-BXD mice do not exhibit significant age-
related decline (adj. P > .1), while inclined screen performance is sig-
nificantly worse with age in the AD-BXD mice (adj. P < .000001),
suggesting a strong interaction between age and genotype on vestibu-
lar function and proprioception. Again, there was no main effect of
sex on inclined screen performance (Sex: F(1,886) = 1.5, P > .1), nor was
there a significant interaction between sex and age (Age*Sex:
F(1,886) = 1.14, P > .1). There was an interaction between sex and
genotype (Genotype*Sex: F(1,886) = 3.87, P < .05), which post hoc
comparisons indicate is due to worse performance by AD mice rela-
tive to their Ntg counterparts, with females affected more than males
(Male adj. P < .005; female adj. P < .000001, Figure 4C).
As with the narrow beam task, we also assessed the impact of
genetic variation on inclined screen performance by examining righting
latency as a function of background strain (Figure 5). Analysis of indi-
vidual strain performance on this task showed a significant main effect
of strain in both Ntg- and AD-BXD strains (StrainNtg: F(26,339) = 2.04,
P < .005; StrainAD: F(27, 474) = 2.2, P < .0005), once again suggesting a
strong influence of naturally occurring genetic variation on vestibular
function and proprioception (Figure 5A). On this task, there was a no
significant interaction between strain and age in either genotype
(Age*StrainNtg: F(24,339) < 1, n.s.; Age*StrainAD: F(25, 450) = 1.2, P > .1).
We found a significant interaction between strain, sex and genotype,
indicating that female mice from AD strains are impaired relative to
male AD strains, which may account for the slight difference in decline
between 6 and 14 m of age shown in Figure 5C. As with narrow beam,
there was no significant correlation between inclined screen perfor-
mance in Ntg-BXD strains compared with AD-BXD strains (females:
r = .21, P > .1, df = 21; males: r = −.13, P > .1, df = 15) (Figure 6A),
suggesting that expressivity of the transgene is not equal across strains,
but instead depends on genetic background. As with narrow beam, h2RIx
estimates indicate that genetic background accounts for much of the
variation in inclined screen performance (Table 1).
Similar to the narrow beam task, we found no correlation
between performance on the inclined screen test and long-term
CFM in male Ntg- and AD-BXD strains or female AD-BXD strains
(Figure 6B,C), suggesting impairments in vestibular function and
proprioception may be independent of cognitive decline. Interest-
ingly, we did observe a significant positive correlation between
inclined screen performance and long-term CFM in female Ntg-
BXD strains (Figure 6C, left); however, it should be noted that
there is very little phenotypic variation in the inclined screen task
compared with CFM, with all female Ntg-BXD strains performing
very well on this task.
3.3 | Muscle strength decreases with age in both
Ntg- and AD-BXD mice
Sarcopenia and muscle weakness are common in aging humans and
grip strength is frequently used to monitor strength in the aging popu-
lation. As in humans, grip strength can be readily assessed in mice and
may show declines in muscle mass and strength in aging mice. To
assess grip strength, mice were allowed to grasp the grip strength
apparatus with all four paws while being held by the tail. Muscle
strength in the fore- and hindlimbs was measured by pulling the
mouse away from the grid by the tail to determine the force exerted
during the animal's attempt to maintain its grip on the bar; greater
force is indicated by more negative values. As shown in Figure 7A,
there was no significant effect of genotype on grip strength, with Ntg
TABLE 1 Heritability estimates for sensorimotor traits in Ntg- and
AD-BXD strains
Ntg-BXD
Trait
Between-strain
variability
Average within-
strain variability
Average
n/strain h2RIx
6 m narrow
beam
667.3893 2351.59 8.68 0.7
14 m
narrow
beam
414.7125 1428.3 7.39 0.7
6 m inclined
screen
63.05047 147.417 8.68 0.8
14 m
inclined
screen
92.87501 425.05 7.39 0.6
6 m grip
strength
0.08793 0.188 8.68 0.8
14 m grip
strength
0.074671 0.179 7.39 0.8
AD-BXD
Trait
Between-strain
variability
Average within-
strain variability
Average
n/strain h2RIx
6 m narrow
beam
734.1014 2697.44 10.77 0.7
14 m
narrow
beam
1357.38 4261.44 9.125 0.7
6 m inclined
screen
90.23455 361.28 10.77 0.7
14 m
inclined
screen
307.7143 1362.3 9.125 0.7
6 m grip
strength
0.135841 0.194 10.77 0.9
14 m grip
strength
0.075719 0.211 9.125 0.8
Note: Heritability (h2RIx) was calculated as the ratio of between-strain
variance (ie, trait variance due to genetic factors) to total variance (ie,
variance due to technical and environmental factors, assessed as within-
strain variance, plus genetic variance) normalized to the average number
of biological replicates per strain (n) according to.23
O'CONNELL ET AL. 5 of 12
and AD mice performing nearly equally (Genotype: F(1,892) < 1, n.s.).
As expected, there was a significant effect of age on grip strength,
with both Ntg and AD mice exhibiting significant decline with age
from 6 to 14 m (Age: F(1,892) = 1444.70, P < .00001) (Figure 7B) and
female mice exhibiting lower grip strength than male mice (Sex:
F(1,892) = 40.97, P < .00001) (Figure 7C). However, there was no signifi-
cant interaction of genotype with age and/or sex, suggesting that all mice
decline similarly with age, regardless of AD carrier status, with female
mice exhibiting the expected sexual dimorphism in muscle strength
(Figure 7C).
We determined the influence of genetic background on grip strength
by assessing average grip strength for each strain at 6 and 14 m
(Figure 8A). As shown in Figure 6A,B, there is significant strain-dependent
variation in grip strength in both Ntg and AD populations (StrainNtg:
F(26, 363) = 3.02, P < .00001; StrainAD: F(27,474) = 4.2, P < .00001) and a sig-
nificant interaction between age and strain (Age*StrainNtg: F(24,363) = 2.6,
P< .00001; Age*StrainAD: F(25,449) = 2.34, P < .0005). Consistent with our
finding that there was no influence of genotype on grip strength, we found
no significant interaction of genotype with strain (F(26,839) < 1, n.s.). Taken
together, these results suggest that age and genetic background profoundly
impact muscle strength and decline and that this is not impacted by the
presence of the AD transgene. As with the other sensorimotor traits
assessed in this study, the correlation between grip strength in the Ntg-
BXD and AD-BXD is not significant, although it is stronger than observed
F IGURE 3 Lack of trait
correlations suggests AD-related
decline in narrow beam performance
has distinct genetic mechanisms from
normal aging or AD-related cognitive
phenotypes. (A) Scatterplot of narrow
beam performance at 14 m of age in
female (left) and male (right) Ntg- and
AD-BXD strains. Narrow beam
performance in 14 m old female (left)
and male (right) plotted against
contextual fear acquisition (CFA)
(A) and contextual fear memory
(CFM) (B). For all panels, each point
represents a strain mean. Black = Ntg-
BXD; red = AD-BXD
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for narrow beam and inclined screen (r = .35, P > .1, df = 21), suggesting
that individual strains may perform more similarly at this task.
4 | DISCUSSION
4.1 | AD-BXD panel recapitulates the exacerbated
age-related sensorimotor deficits associated with AD
Although dementia and cognitive decline are the hallmark diagnostic
symptoms of AD in humans, many AD patients also experience
impairments in noncognitive domains, including phenotypes associ-
ated with sensorimotor function such as coordination, balance, muscle
strength and proprioception.2-4,6,27-29 In this study, we investigated
the impact of naturally occurring genetic variation on age- and AD-
related sensorimotor decline using our recently developed AD-BXD
genetic reference panel.19 There was significant variation in balance,
coordination and vestibular function—both Ntg- and AD-BXD mice
showed age-related declines in these phenotypes and the presence of
familial AD mutations in the AD-BXD mice exacerbated this decline.
There was a significant effect of sex on AD-related motor decline,
with female AD-BXD mice exhibiting greater impairment on motor
phenotypes than male AD-BXD mice. We found no relationship
between motor function and decline in Ntg- and AD-BXD strains.
Finally, although there was a pronounced effect of age on grip
F IGURE 4 Impairments in motor coordination, vestibular function and proprioception are exacerbated by the AD transgene. (A) Mice carrying
the 5XFAD transgene take significantly longer to right themselves on the inclined screen apparatus, indicating impaired proprioception and
vestibular function. (B) Stratification of inclined screen performance by age and (C) by age and sex. Each point represents a strain average and
statistical outliers are indicated by a + sign. *** = adj. P < .0001 following post hoc testing using Tukey's HSD
F IGURE 5 Genetic background
influences vestibular function and
proprioception on the inclined screen
task in both normal aging and
AD. (A) Mean righting time on the
inclined screen averaged by strain in
6 m old Ntg-BXD (left) and AD-BXD
(right) strains. (B) Mean righting time
on the inclined screen average by
strain in 14 m old Ntg-BXD and AD-
BXD strains. (C) Average age-related
decline by strain in the Ntg-BXD
(left) and AD-BXD (right) panels.
Decline was calculated by
subtracting performance at 6 m of
age from that measured at 14 m of
age. Data are presented as mean
± SEM. In all panels, number on the
x-axis indicates the BXD strain used
to generate each line.
*** = P < .0001
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strength, we did not observe an effect of transgene on this
phenotype.
4.2 | Influence of genetic background on
sensorimotor traits and impact of the AD transgene on
decline
We recently developed the first mouse model of genetic diversity in
AD- the AD-BXDs - and showed that the inclusion of naturally occur-
ring genetic variation introduces significant phenotypic variation in
cognitive traits, including long-term memory. Specifically, despite all
strains carrying the same high-risk 5XFAD transgene, some strains
exhibit resilience to cognitive impairment while others show increased
susceptibility.19 We now extend that analysis to sensorimotor traits,
including coordination, balance, vestibular function and muscle
strength. Similar to what we observed for cognitive abilities, there
was a significant impact of genetic background on both baseline per-
formance on motor tasks and both age- and AD-related decline. As
with long-term memory, some strains exhibit resilience to age-related
and/or AD-related impairments, exhibiting little decline with age,
regardless of genotype. In contrast, some strains even showed
improvement with age, suggesting modifier genes exist that influence
F IGURE 6 Lack of trait
correlations indicates AD-related
declines in righting on the inclined
screen are controlled by distinct
genetic mechanisms from either
normal aging or AD-related cognitive
phenotypes. (A) Scatterplot of
inclined screen performance at 14 m
of age in female (left) and male (right)
Ntg- and AD-BXD strains. Inclined
screen performance in 14 m old
female (left) and male (right) plotted
against contextual fear acquisition
(CFA) (A) and contextual fear memory
(CFM) (B). For all panels, each point
represents a strain mean.
Black = Ntg-BXD; red = AD-BXD
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both the normal motor function-related aging process and AD-related
decline in motor abilities.
Humans exhibit substantial variation in longevity and
healthspan,30-32 including the development of frailty and physical
impairment in old age.27 Moreover, only a subset of AD patients exhibit
motor-related impairments.4,6,33,34 The Ntg- and AD-BXD panel
exhibits similar phenotypic variation, suggesting that these panels rep-
resent a key resource for investigating the influence of genetic variation
on age- and AD-related frailty and motor decline. Heritability (h2) esti-
mates for all three sensorimotor domains evaluated in this study range
from 0.6 to 0.9 (Table 1),23 suggesting a strong influence of genetic
background on these phenotypes. Thus, future studies will exploit the
power of the AD-BXD panel as a mapping population to identify poten-
tial candidate modifier genes, which may represent novel targets for
addressing sensorimotor decline in both normal aging and AD.
4.3 | Sex differences in AD-related motor decline
Although overall we did not find a significant main effect of sex on
either the narrow beam or inclined screen phenotypes, for both traits
F IGURE 7 Age, but not sex or genotype, is associated with loss of grip strength. (A) Grip strength in all four paws in Ntg- and AD-BXD
strains. (B) Grip strength stratified by age and (C) by age and sex. Each point represents a strain average and statistical outliers are indicated by
a + sign
F IGURE 8 Genetic background
influences grip strength in both Ntg-
and AD-BXD strains. (A) Mean grip
strength in all four paws per strain in
6 m old Ntg-BXD (left) and AD-BXD
(right) strains. (B) Mean grip strength
in all four paws in 14 m old Ntg-BXD
(left) and AD-BXD (right) strains.
(C) Average-age related decline in
four-paw grip strength in the Ntg-
BXD (left) and AD-BXD (right) panels.
Decline was calculated by subtracting
grip strength at 6 m of age from that
measured at 14 m of age. Data are
presented as mean ± SEM. In all
panels, number on the x-axis
indicates the BXD strain used to
generate each line
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we did find significant interactions between sex and age or genotype
(Figures 1 and 4), with females performing worse than males in both
instances. Thus, the mechanisms underlying both age-related and AD-
related declines in vestibular function, balance and proprioception are
exacerbated in females. This is consistent overall with reports that the
incidence of AD is higher in women and that women are at higher risk
of developing AD or a related dementia.35-38 However, there are rela-
tively few reports on motor phenotypes in AD and fewer still that
stratify by sex, making comparisions between human studies and ani-
mal models difficult. In one study examining the relationship between
gait speed decline and conversion to mild cognitive impairment (MCI)
in men and women, women progress more rapidly to MCI once gait
speed begins to decrease.39
4.4 | AD-related motor decline is likely distinct from
both AD-related cognitive decline and normal age-
related decline
Frailty and motor decline are common in aging humans,27 thus one
possible explanation for the increased motor decline observed in both
humans with AD and the AD-BXDs is that the AD disease process
acts to accelerate “normal” age-related motor decline.2,3 However, the
lack of an observed correlation between two highly robust cognitive
traits (CFA and CFM) and sensorimotor traits - despite the high
degree of heritability for all of these traits (Table 1)19 suggests that
cognitive traits are controlled by distinct genetic mechanisms than the
sensorimotor traits investigated here. In the two tasks that exhibited
sensitivity to the AD transgene, narrow beam and incline screen, we
found no correlation between the performance of the Ntg strains
compared with the AD-BXD strains, suggesting that the underlying
genetic mechanisms regulating motor impairment in these two models
is distinct. There is similarly no correlation between sensorimotor and
cognitive performance across the AD-BXD panel, including the Ntg-
BXD strains,19 suggesting that AD-related motor impairment is dis-
tinct from both AD and age-related cognitive decline. Thus, potential
therapeutics targeted at memory loss and cognitive decline are
unlikely to be effective at treating motor-related deficits and may not
forestall the loss of independence and need for long-term care in
patients, emphasizing the urgent need to better understand the
impact of AD on noncognitive domains.
4.5 | Limitations of this study
Notably, although grip strength has been reported to be associated
with AD risk in humans,2,3 we did not detect an effect of AD geno-
type on grip strength in the AD-BXD panel at either age tested,
although there was a pronounced effect of age on muscle strength in
both Ntg- and AD-BXD mice. However, there are several reports in
human cohorts that indicate that lower extremity dysfunction is more
closely associated with mild cognitive impairment (MCI) and AD than
upper limb function.33,40-43 Our assessment of grip strength measured
force exerted by all four limbs in each mouse and thus cannot distin-
guish between differential impairments between the forelimbs and
hindlimbs in mice, although the narrow beam and inclined screen tasks
would likely be sensitive to limb-specific decline. Additionally, it is
important to note that expression of the 5XFAD transgene used to
generate the AD-BXD reference panel is driven by a Thy-1 promoter
and likely does not fully recapitulate the endogenous pattern or amy-
loid pathology or presenilin expression in the periphery. This limitation
can be overcome by the use of a “knockin” model in which human
mutations in App and Psen1 are controlled by the endogenous pro-
moters for both genes to produce a more translationally-relevant
organism-wide expression pattern in both the CNS and peripheral
tissues.
In human AD patients, motor impairment has been reported to
occur prior to the onset of cognitive symptoms,2,3,6,33 but in the AD-
BXD panel we did not observe significant impairment on any of the
sensorimotor tasks used in this study at the earliest age measured
(6 m). While we cannot exclude the possibility that motor decline does
not precede cognitive deficits in the AD-BXDs, a limitation of our
study design is that motor function was measured at only two ages,
6 and 14 m. The average age at onset for cognitive impairment in the
AD-BXD panel is ~10 m,19 thus motor performance at 6 m of age may
simply be too early of an age to detect a preclinical decline in sensori-
motor function in the AD-BXDs. In support of this hypothesis,
although not significant (P > .05), we do see a trend for worse narrow
beam performance in the AD-BXDs compared with Ntg-BXDs at 6 m
of age (Figure 1B).
Some caution is warranted in the interpretation of narrow beam
data when considering the behavior of mice during this task. We
report strains with averages of latency >120 seconds (Figure 1C),
suggesting that some strains have a large number of animals that sim-
ply did not move while on the beam or failed to remain on the beam.
As a result, in some cases, an increase in time to cross the beam may
not necessarily be due to an impairment of sensorimotor performance,
but rather another behavioral output such as anxiety that influences
performance on these tasks.
Genetic reference panels such as the BXD family used here repre-
sent powerful tools for the analysis and genetic mapping of quantita-
tive traits such as the sensorimotor traits investigated here. As such,
they are ideal for discovering new genetic loci associated with com-
plex traits.44 The high degree of heritability for the traits we examined
here (h2RIx ≈0.6-0.9) suggests they are amenable to QTL mapping to
identify candidate genes and loci associated with sensorimotor perfor-
mance. However, the number of strains used in the present study is
insufficient for this approach and additional strains will be needed to
ensure we are adequately powered for such analysis. That said, we
are still able to investigate the relative contributions of the two paren-
tal genomes of the BXD family (C57Bl/6J and DBA/2J) and how their
influence may differ between cognitive and noncognitive phenotypes.
For example, we recently reported that the B6 genetic background
confers resilience to the cognitive effects of the 5XFAD transgene.19
However, the B6 and D2 genomes may influence motor-related phe-
notypes differently from cognitive phenotypes, as evidenced by the
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lack of correlation between contextual fear memory and acquisition
and the narrow beam and inclined screen tasks (Figures 3 and 5).
4.6 | Conclusions
The results presented here provide further evidence for the transla-
tional utility of our novel AD-BXD panel, which we now show also
exhibits sensorimotor decline similar to that reported in human AD
patients. Moreover, this decline is strongly modified by genetic back-
ground and exhibits a high degree of heritability, consistent with the
human disease. Thus, the AD-BXD panel represents a novel tool to
investigate sensorimotor deficits in normal aging and AD and facilitate
the discovery of novel targets to address these deficits. Our finding
that there is no correlation between motor and cognitive phenotypes
in either the AD strains or the normal aging controls indicates that
motor decline likely occurs via a mechanism distinct from cognitive
decline in both AD and normal aging individuals. Future work will
incorporate additional strains for genome-wide mapping to identify
potential modifier genes and omics analysis of CNS regions associated
with sensorimotor tasks.
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